Jaguar Animal Health (NASDAQ: JAGX) is an animal health company focused on the development and commercialization of first-in-class gastrointestinal products for companion and production animals, foals, and high-value horses. The company’s lead prescription drug product candidate, Canalevia^™, is intended for the treatment of various forms of diarrhea in dogs. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm^™ in six additional target species, formulations of SB-300 in horses, and Canalevia^™ for cats and dogs. For more information, visit the company’s website at www.jaguaranimalhealth.com